alx oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer
Biotechnology Research
South San Francisco, california
Founded in 2015
11-50 employees
alx oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the cd47 checkpoint pathway and bridge the innate and adaptive immune system. alx oncology’s lead product candidate, evorpacept (also known as alx148), is a next generation cd47 blocking therapeutic that combines a high-affinity cd47 binding domain with an inactivated, proprietary fc domain. evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents.
Company Information
- Industry
- Biotechnology Research
- Company Type
- Public Company
- Founded
- 2015
- Employee Range
- 11-50
- Revenue Range
- $5,000,000 - $10,000,000
Location
- Address
- 323 allerton ave
- City
- South San Francisco
- Region
- california
- Postal Code
- 94080
- Country
- United States
Specialties
Immuno-oncologyNovel BiologicsResearch And DevelopmentInnovationCd47
